The FDA approved a supplement to Samsung Bioepis's biologics licence application BLA 761202 for BYOOVIZ, ranibizumab-nuna, on 1 September 2026. A supplement is a change to an already licensed product - it can cover manufacturing, a presentation, labelling or an added indication - and the approval record as harvested does not say which. Read it as a maintenance action on a marketed biosimilar, not as a new approval.
What it does confirm is that ranibizumab biosimilars remain an active regulatory file rather than a settled one, which matters where biosimilar substitution is being used to bring the cost of anti-VEGF treatment down. If your pharmacy stocks this product, the specific change will appear in the revised prescribing information rather than in the approval listing, and that is the document to read before assuming nothing has changed.
India's position is separate and is not addressed by an FDA action. Ranibizumab biosimilars have been licensed and marketed here for years under CDSCO, so a US supplement has no direct bearing on what is available in an Indian pharmacy; treat this as intelligence about the international file, not as a change to Indian supply.
- Check the revised prescribing information rather than the approval listing for what actually changed.
- Do not describe this as a new approval or a new indication; the record supports neither.
- Keep biosimilar brand and batch recorded in the notes for any intravitreal injection.
- Nothing here alters CDSCO status or Indian availability of ranibizumab biosimilars.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for ophthalmology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free